Quest Diagnostics (DGX) Q4 FY2025 earnings: revenue $2.8 billion, up 7.1% on the year
Quest Diagnostics Inc. (DGX) reported revenue of $2.8 billion for Q4 FY2025, the quarter ended 31 December 2025, up 7.1% on the same quarter a year earlier. Net income was $245 million, up 10.4% on the year, and diluted earnings per share $2.18. The figures are the company's own, from the 10-K it filed with the SEC on 26 February 2026.
Revenue
$2.8 billion
+7.1% on the year · -0.4% on the quarter
Q1 FY2024Q4 FY2025
Operating margin
13.8%
13.8% a year earlier
Q1 FY2024Q4 FY2025
Net income
$245 million
+10.4% on the year · 0.0% on the quarter
Q1 FY2024Q4 FY2025
Diluted EPS
$2.18
+11.8% on the year · +0.9% on the quarter
Q1 FY2024Q4 FY2025
this quarterthe same quarter a year earlierHover a bar for its figure.
What management said
Guidance figures: 9 new.
Full-year revenue rose 11.8%: Full-year net revenues were $11.04 billion, up 11.8% from 2024. Fourth-quarter net revenues were $2.81 billion, up 7.1%.
Full-year reported diluted EPS up 13.8%: Full-year reported diluted EPS was $8.75, up 13.8%, and adjusted diluted EPS was $9.85, up 10.3%. Fourth-quarter reported diluted EPS was $2.18, up 11.8%.
Requisition volume drove revenue growth: Requisition volume rose 12.3% for the year and 8.5% in the fourth quarter. Organic requisition volume rose 3.4% for the year and 7.9% in the fourth quarter. Revenue per requisition was down 0.1% in the quarter.
$ million except per share. Read moreFourth quarters are the year less the first three quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
Q4 FY2025
Q3 FY2025
Q4 FY2024
On the quarter
On the year
Last 8 quarters
Operating cash flow
465
563
464
-17.4%
+0.2%
Capital expenditure
158
144
123
+9.7%
+28.5%
Free cash flow
307
419
341
-26.7%
-10.0%
Free cash flow margin
10.9%
14.9%
13.0%
Cash from investing
-191
-201
-502
Cash from financing
-287
-247
-170
Depreciation and amortisation
145
142
135
+2.1%
+7.4%
Share-based compensation
25.0
20.0
27.0
+25.0%
-7.4%
Buybacks
n/a
150
n/a
Dividends paid
90.0
89.0
84.0
+1.1%
+7.1%
Dividend per share
$0.80
$0.80
$0.75
0.0%
+6.7%
Diluted shares, weighted
112m
113m
113m
-0.9%
-0.9%
Shares outstanding at period end
110m
111m
111m
-1.2%
-1.0%
Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.
Balance sheet
$ million
Q4 FY2025
Q3 FY2025
Q4 FY2024
On the quarter
On the year
Last 8 quarters
Shareholders' equity
7,170
7,258
6,778
-1.2%
+5.8%
Non-controlling interest
36.0
37.0
35.0
-2.7%
+2.9%
Redeemable equity
80.0
81.0
83.0
-1.2%
-3.6%
Debt
5,671
5,675
6,217
-0.1%
-8.8%
Operating lease liabilities
537
534
535
+0.6%
+0.4%
Finance lease liabilities
18.0
n/a
16.0
+12.5%
Other liabilities
2,713
2,612
2,489
+3.9%
+9.0%
Total liabilities and equity
16,225
16,197
16,153
+0.2%
+0.4%
Fixed assets
2,203
2,145
2,113
+2.7%
+4.3%
Goodwill
8,945
8,901
8,856
+0.5%
+1.0%
Intangible assets
1,636
1,662
1,763
-1.6%
-7.2%
Securities held for sale or to maturity
0.0
n/a
0.0
Trading assets
78.0
n/a
n/a
Cash and equivalents
420
432
549
-2.8%
-23.5%
Receivables
1,408
1,456
1,304
-3.3%
+8.0%
Inventory
189
186
188
+1.6%
+0.5%
Other assets
1,346
1,415
1,380
-4.9%
-2.5%
Total assets
16,225
16,197
16,153
+0.2%
+0.4%
Questions
What was Quest Diagnostics' revenue in Q4 FY2025?
Quest Diagnostics (DGX) reported revenue of $2.8 billion for Q4 FY2025, the quarter ended 31 December 2025, up 7.1% on the same quarter a year earlier.
How much did Quest Diagnostics earn in Q4 FY2025?
Net income for Q4 FY2025 was $245 million, up 10.4% on the year, and diluted earnings per share $2.18.
When did Quest Diagnostics report Q4 FY2025 results?
Quest Diagnostics filed its 10-K for the year that ended with the quarter on 26 February 2026; the fourth quarter is the year less the first three.
Each quarter as filed, linked to its filing. Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.
10-K for the period ended 31 December 2025, filed 26 February 2026: the filing.